TY - JOUR
T1 - Clearance Mechanisms of Atrial and Brain Natriuretic Peptides in Rats
AU - Hashimoto, Yukiya
AU - Nakao, Kazuwa
AU - Hama, Norio
AU - Imura, Hiroo
AU - Mori, Sachiyo
AU - Yamaguchi, Masayuki
AU - Yasuhara, Masato
AU - Hori, Ryohei
PY - 1994/1
Y1 - 1994/1
N2 - To assess clearance mechanisms of atrial and brain natriuretic peptides in the circulation, we examined the effects of a neutral endopeptidase (NEP) inhibitor and a clearance receptor ligand on plasma concentrations of the peptides in normal rats. Plasma concentrations of endogenous α-rat atrial natriuretic peptide (α-rANP) were not significantly elevated by intravenous infusion of a NEP inhibitor, phosphoramidon, but were elevated threefold by intravenous infusion of a clearance receptor ligand, des(Gln18-Gly22)-rANP4−23-NH2 [C-ANF4−23]. On the other hand, the clearance of α-rANP given intravenously at the pharmacological dose, 600 pmol/ min/kg for 2 min, was decreased to one-third by the administration of phosphoramidon, although the administration of C-ANF4−23 did not significantly decrease the clearance. The clearance of rat brain natriuretic peptide (rBNP) given at 600 pmol/min/kg for 2 min was approximately 38% lower than that of α-rANP. The effect of phosphoramidon on the clearance of rBNP was not significant and was similar to that of C-ANF4−23. These results suggest that clearance receptor is involved in the clearance of the physiological levels of α-rANP and that NEP plays a major role in the clearance of a pharmacological dose of α-rANP, at which clearance receptors are thought to be saturated, and also indicate a pharmacokinetic difference between α-rANP and rBNP.
AB - To assess clearance mechanisms of atrial and brain natriuretic peptides in the circulation, we examined the effects of a neutral endopeptidase (NEP) inhibitor and a clearance receptor ligand on plasma concentrations of the peptides in normal rats. Plasma concentrations of endogenous α-rat atrial natriuretic peptide (α-rANP) were not significantly elevated by intravenous infusion of a NEP inhibitor, phosphoramidon, but were elevated threefold by intravenous infusion of a clearance receptor ligand, des(Gln18-Gly22)-rANP4−23-NH2 [C-ANF4−23]. On the other hand, the clearance of α-rANP given intravenously at the pharmacological dose, 600 pmol/ min/kg for 2 min, was decreased to one-third by the administration of phosphoramidon, although the administration of C-ANF4−23 did not significantly decrease the clearance. The clearance of rat brain natriuretic peptide (rBNP) given at 600 pmol/min/kg for 2 min was approximately 38% lower than that of α-rANP. The effect of phosphoramidon on the clearance of rBNP was not significant and was similar to that of C-ANF4−23. These results suggest that clearance receptor is involved in the clearance of the physiological levels of α-rANP and that NEP plays a major role in the clearance of a pharmacological dose of α-rANP, at which clearance receptors are thought to be saturated, and also indicate a pharmacokinetic difference between α-rANP and rBNP.
KW - atrial natriuretic peptide
KW - brain natriuretic peptide
KW - clearance receptor
KW - neutral endopeptidase
KW - phosphoramidon
UR - https://www.scopus.com/pages/publications/0028096121
U2 - 10.1023/A:1018941626731
DO - 10.1023/A:1018941626731
M3 - 記事
C2 - 8140057
AN - SCOPUS:0028096121
SN - 0724-8741
VL - 11
SP - 60
EP - 64
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 1
ER -